MDR A. baumannii
Acinetobacter baumannii has emerged as a predominant cause of hospital-acquired infections worldwide, posing a significant challenge due to its extraordinary ability to acquire resistance to multiple antibiotics. According to recent data, infections caused by multidrug-resistant A. baumannii lead to increased morbidity, longer hospital stays, and higher healthcare costs. Carbapenems and tigecycline have historically provided reliable treatment for A. baumannii infections; however, recent global trends indicate a significant increase in carbapenem and tigecycline resistance among circulating isolates